Company Filing History:
2 out of 131,611 
2 out of 124 
1 out of 8 Years Active: 2017-2018
Title: The Innovative Contributions of Keunchil Park
Introduction
Keunchil Park is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of drug delivery systems, particularly focusing on poorly water-soluble drugs. With a total of three patents to his name, Park's work is aimed at improving cancer treatment methodologies.
Latest Patents
Among his latest patents is a targeted poorly water-soluble drug delivery system, which includes a method of preparing the same and a pharmaceutical composition. This innovative system is designed to specifically target cancer cells, allowing for the effective delivery of poorly water-soluble drugs. The system can control the type of cancer cell targeting material that reacts to antigens overexpressed in cancer cells. This capability enables the binding of the drug delivery system to the cancer cell surface, enhancing the therapeutic efficacy of the encapsulated drugs based on the type of cancer and treatment goals. Another significant patent involves using PDGF as a biomarker for predicting resistance or the effectiveness of c-Met targeting drugs. This method evaluates the efficacy of c-Met targeting agents by measuring the levels of PDGF protein and its coding gene.
Career Highlights
Keunchil Park has worked with prominent organizations, including Samsung Electronics and the Samsung Life Public Welfare Foundation. His experience in these companies has contributed to his expertise in developing innovative solutions in the pharmaceutical field.
Collaborations
Park has collaborated with notable colleagues such as Youngwook Kim and Jae Young Choi, further enhancing the impact of his work in drug delivery systems.
Conclusion
Keunchil Park's innovative contributions to drug delivery systems demonstrate his commitment to advancing cancer treatment. His patents reflect a deep understanding of the challenges in delivering poorly water-soluble drugs effectively. Through his work, Park continues to make strides in improving therapeutic outcomes for cancer patients.